Articles

While artificial intelligence offers promising applications in healthcare, such as generating clinical summaries and estimating risks, its integration is hindered by limitations in EHR systems and the need for further model development Read More ›

A new study highlights the potential of serial liquid biopsies to monitor treatment response and uncover dynamic genomic changes in patients with metastatic breast cancer. Read More ›

Patients with metastatic breast cancer prefer oral endocrine therapy because of convenience, while healthcare providers recognize the benefits of oral and intramuscular options. Read More ›

Imlunestrant, a novel oral SERD, demonstrates promising efficacy and safety in a phase 3 trial for advanced breast cancer patients. Read More ›

Early results from the SERENA-1 trial show camizestrant combined with ribociclib may be safe and effective for treating estrogen receptor–positive/HER2-negative advanced breast cancer. Read More ›

A new study shows promising real-world results for elacestrant in advanced breast cancer patients with ESR1 mutations, exceeding prior clinical trial data. Read More ›

Ongoing trials suggest that combining elacestrant with other therapies may offer a safe and effective treatment option for estrogen receptor–positive/HER2-negative metastatic breast cancer. Read More ›

While SERDs have a storied history, advancements of newer agents like elacestrant and imlunestrant have been successful in overcoming limitations of older treatments Read More ›

Liquid biopsy using ctDNA analysis is transforming breast cancer care, offering potential for personalized treatment, early detection, and monitoring response. Read More ›

The PADMA phase 3 trial demonstrated that combining palbociclib with endocrine therapy significantly outperformed standard chemotherapy in treating high-risk HR-positive/HER2-negative metastatic breast cancer. Read More ›